Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | KDM6B | O15054 | 1/20 | 0.54 |
| ▸ | KDM5C | P41229 | 1/20 | 0.54 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.54 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.54 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.48 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1880283 | 0.81 | ALDH1A1 (0.50) | L3MBTL1MAPTKMT2AMEN1NPC1 | |
| SCHEMBL11899688 | 0.80 | MAPT (0.36) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL11621309 | 0.80 | KDM5C (0.53) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL11616143 | 0.79 | HDAC6 (0.46) | KDM4EHTT | |
| SCHEMBL11898493 | 0.79 | MAPT (0.35) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL11618571 | 0.78 | ALDH1A1 (0.42) | KDM4EMAPTKMT2AHTTPOLB | |
| SCHEMBL1681636 | 0.78 | ALDH1A1 (0.50) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL11620111 | 0.78 | TSHR (0.50) | KDM4EKDM5CL3MBTL1MAPTKMT2A | |
| SCHEMBL31036600 | 0.78 | TSHR (0.50) | KDM4EKDM5CL3MBTL1MAPTKMT2A | |
| SCHEMBL11619281 | 0.78 | ALDH1A1 (0.51) | KDM4EMAPTKMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160114060-A1 | PSMA-BINDING AGENTS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-04-28 | — | — | US | disclosed |
| US-20110142760-A1 | PSMA-BINDING AGENTS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-06-16 | — | — | US | disclosed |
| US-7429594-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1656366-A1 | SUBSTITUTED PYRIMDINONE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1448564-B1 | SUBSTITUTED INDOLIZINE-LIKE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-7026326-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-6921762-B2 | Substituted indolizine-like compounds and methods of use | AMGEN INC. (US) | 2005-07-26 | — | — | US | disclosed |
| WO-2005019202-A1 | SUBSTITUTED PYRIMDINONE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043301-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-02-24 | — | — | US | disclosed |
| US-20050038010-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-02-17 | — | — | US | disclosed |
| US-20030069425-A1 | Substituted pyrimidine compounds and methods of use | AMGEN INC. | 2003-04-10 | — | — | US | disclosed |
| US-6420385-B1 | INFLAMMATORY, PAIN AND DIABETES DISEASES, | AMGEN INC. | 2002-07-16 | — | — | US | disclosed |
| US-6410729-B1 | ANALGESICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATORY AGENTS | AMGEN INC. | 2002-06-25 | — | — | US | disclosed |
| US-6096753-A | Substituted pyrimidinone and pyridone compounds and methods of use | AMGEN INC. (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0948496-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDONE COMPOUNDS AND METHODS OF USE | Amgen inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0948497-A2 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE | Amgen inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998024780-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDINONE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024782-A2 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| US-4098893-A | PYRIDINE DERIVATIVES AND THEIR USE AS ANTICOCCIDIAL AGENTS | SANKYO COMPANY LIMITED (JP) | 1978-07-04 | — | — | US | disclosed |
| US-4054663-A | POULTRY FEEDS | SANKYO COMPANY LIMITED (JA) | 1977-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110142760-A1 | PSMA-BINDING AGENTS AND USES THEREOF | KLK3, FOLH1, DNPEP | KDM4E 177/4885KDM6B 223/4885KDM5C 138/4885 |
| US-20050043301-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MYLK, MCL1 | KDM4E 4282/4885KDM6B 4410/4885KDM5C 3922/4885 |
| US-20030069425-A1 | Substituted pyrimidine compounds and methods of use | DPYD, IL6, IL1B | KDM4E 3964/4885KDM6B 1938/4885KDM5C 2345/4885 |
| US-20160114060-A1 | PSMA-BINDING AGENTS AND USES THEREOF | KLK3, FOLH1, DNPEP | KDM4E 177/4885KDM6B 223/4885KDM5C 138/4885 |
| US-20050038010-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MYLK, MCL1 | KDM4E 4282/4885KDM6B 4410/4885KDM5C 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.